KindlyMD (NASDAQ:NAKA) CEO David Bailey Purchases 55,115 Shares of Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey purchased 55,115 shares of KindlyMD stock in a transaction dated Thursday, May 28th. The stock was bought at an average price of $5.62 per share, with a total value of $309,746.30. Following the completion of the transaction, the chief executive officer owned 3,175,476 shares of the company’s stock, valued at $17,846,175.12. This represents a 1.77% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

KindlyMD Stock Performance

Shares of NASDAQ NAKA opened at $5.60 on Friday. The stock has a market cap of $97.44 million, a PE ratio of -0.13 and a beta of 17.12. KindlyMD, Inc. has a fifty-two week low of $4.50 and a fifty-two week high of $995.60. The stock has a fifty day moving average of $8.21 and a 200-day moving average of $13.07.

KindlyMD (NASDAQ:NAKA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($15.20) earnings per share for the quarter. The company had revenue of $2.68 million during the quarter. KindlyMD had a negative net margin of 7,397.12% and a negative return on equity of 81.32%. On average, sell-side analysts predict that KindlyMD, Inc. will post -16.8 EPS for the current year.

Key KindlyMD News

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David Bailey bought 104,833 shares at an average price of $4.84, adding to a series of recent open-market purchases and lifting his ownership stake, which may reassure investors about management’s confidence in KindlyMD. Article Title
• Positive Sentiment: Maxim Group reiterated a Buy rating and $30 price target, with forecasted improvement in later-period earnings, which could help support sentiment around NAKA. Article Title
• Neutral Sentiment: Maxim’s earnings estimates still call for losses in the near term, but they model a shift to profitability in some periods of fiscal 2027, suggesting the turnaround story remains speculative. Article Title
• Negative Sentiment: The company’s latest reported quarter showed a large EPS loss and weak profitability metrics, which continue to highlight execution risk for investors. Article Title

Institutional Investors Weigh In On KindlyMD

Several hedge funds have recently added to or reduced their stakes in the company. Alyeska Investment Group L.P. bought a new stake in KindlyMD during the fourth quarter worth about $8,993,000. ParaFi Capital LP bought a new stake in KindlyMD during the third quarter worth about $443,055,000. Hunting Hill Global Capital LLC bought a new stake in KindlyMD during the fourth quarter worth about $4,672,000. RK Capital Management LLC FL bought a new stake in KindlyMD during the third quarter worth about $239,052,000. Finally, Yorkville Advisors Global LP bought a new stake in KindlyMD during the third quarter worth about $231,942,000.

Analysts Set New Price Targets

Several research firms recently issued reports on NAKA. Maxim Group dropped their price objective on KindlyMD from $60.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, April 6th. B. Riley Financial dropped their price objective on KindlyMD from $40.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, February 23rd. Weiss Ratings raised KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Wall Street Zen raised KindlyMD to a “sell” rating in a research note on Saturday, May 23rd. Finally, TD Cowen began coverage on KindlyMD in a research note on Friday, April 10th. They set a “buy” rating and a $40.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $30.00.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.